The company said that growth in its diagnostics business was partly offset by declines in the Americas and China.
The company said that its molecular diagnostics revenues rose 7 percent on the strength of its women's health assays and Biotheranostics business.
Cubit Diagnostics announced on Tuesday that it has been awarded $2.6 million by the National Institutes of Health's Rapid Acceleration of Diagnostics (RADx) Tech program. The funding will enable the ...
The bank had suspended its rating and price target for Tempus during its $600 million acquisition of Ambry Genetics due to TD Securities' involvement in the deal.